Sweeney CJ - Search Results

1

Addition of docetaxel or bisphosphonates to standard of care in men with localised or metastatic, hormone-sensitive prostate cancer: a systematic review and meta-analyses of aggregate data.

Vale CL, Burdett S, Rydzewska LHM, Albiges L, Clarke NW, Fisher D, Fizazi K, Gravis G, James ND, Mason MD, Parmar MKB, Sweeney CJ, Sydes MR, Tombal B, Tierney JF; STOpCaP Steering Group. Vale CL, et al. Among authors: sweeney cj. Lancet Oncol. 2016 Feb;17(2):243-256. doi: 10.1016/S1470-2045(15)00489-1. Epub 2015 Dec 21. Lancet Oncol. 2016. PMID: 26718929 Free PMC article. Review.

2

Preface. Prostate cancer.

Sweeney CJ. Sweeney CJ. Hematol Oncol Clin North Am. 2013 Dec;27(6):xi-xii. doi: 10.1016/j.hoc.2013.10.006. Hematol Oncol Clin North Am. 2013. PMID: 24188263 No abstract available.

3

Elevated IL-8, TNF-α, and MCP-1 in men with metastatic prostate cancer starting androgen-deprivation therapy (ADT) are associated with shorter time to castration-resistance and overall survival.

Sharma J, Gray KP, Harshman LC, Evan C, Nakabayashi M, Fichorova R, Rider J, Mucci L, Kantoff PW, Sweeney CJ. Sharma J, et al. Among authors: sweeney cj. Prostate. 2014 Jun;74(8):820-8. doi: 10.1002/pros.22788. Epub 2014 Mar 26. Prostate. 2014. PMID: 24668612

4

Management of metastatic hormone-sensitive prostate cancer.

Bernard B, Sweeney CJ. Bernard B, et al. Among authors: sweeney cj. Curr Urol Rep. 2015 Mar;16(3):14. doi: 10.1007/s11934-015-0488-8. Curr Urol Rep. 2015. PMID: 25677237 Review.

5

Sequencing current therapies in the treatment of metastatic prostate cancer.

Valenca LB, Sweeney CJ, Pomerantz MM. Valenca LB, et al. Among authors: sweeney cj. Cancer Treat Rev. 2015 Apr;41(4):332-40. doi: 10.1016/j.ctrv.2015.02.010. Epub 2015 Mar 4. Cancer Treat Rev. 2015. PMID: 25784591 Review.

6

Risk of prostate cancer mortality in men with a history of prior cancer.

Dinh KT, Mahal BA, Ziehr DR, Muralidhar V, Chen YW, Viswanathan VB, Nezolosky MD, Beard CJ, Choueiri TK, Martin NE, Orio PF, Sweeney CJ, Trinh QD, Nguyen PL. Dinh KT, et al. Among authors: sweeney cj. BJU Int. 2016 Jun;117(6B):E20-8. doi: 10.1111/bju.13144. Epub 2015 May 23. BJU Int. 2016. PMID: 25845283

7

Statin Use at the Time of Initiation of Androgen Deprivation Therapy and Time to Progression in Patients With Hormone-Sensitive Prostate Cancer.

Harshman LC, Wang X, Nakabayashi M, Xie W, Valenca L, Werner L, Yu Y, Kantoff AM, Sweeney CJ, Mucci LA, Pomerantz M, Lee GS, Kantoff PW. Harshman LC, et al. Among authors: sweeney cj. JAMA Oncol. 2015 Jul;1(4):495-504. doi: 10.1001/jamaoncol.2015.0829. JAMA Oncol. 2015. PMID: 26181260 Free PMC article.

8

Chemohormonal Therapy in Metastatic Hormone-Sensitive Prostate Cancer.

Sweeney CJ, Chen YH, Carducci M, Liu G, Jarrard DF, Eisenberger M, Wong YN, Hahn N, Kohli M, Cooney MM, Dreicer R, Vogelzang NJ, Picus J, Shevrin D, Hussain M, Garcia JA, DiPaola RS. Sweeney CJ, et al. N Engl J Med. 2015 Aug 20;373(8):737-46. doi: 10.1056/NEJMoa1503747. Epub 2015 Aug 5. N Engl J Med. 2015. PMID: 26244877 Free PMC article. Clinical Trial.

9

The Juxtaposition of Population Science and Individual Treatment Recommendations for Intermittent Androgen Deprivation Therapy.

Sweeney CJ. Sweeney CJ. JAMA Oncol. 2015 Dec;1(9):1270-1. doi: 10.1001/jamaoncol.2015.3005. JAMA Oncol. 2015. PMID: 26379098 No abstract available.

10

It Is Time to Harmonize the Design and Conduct of Clinical Trials in Metastatic Hormone-sensitive Prostate Cancer.

Sridhar SS, Sweeney CJ. Sridhar SS, et al. Among authors: sweeney cj. Eur Urol. 2016 Aug;70(2):263-4. doi: 10.1016/j.eururo.2015.11.025. Epub 2015 Dec 9. Eur Urol. 2016. PMID: 26683759 No abstract available.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

285 results

Search Page

Filters